Pharmacokinetics of mirtazapine and its main metabolites in Beagle dogs: a pilot study

Area of Science:

• Veterinary Pharmacology
• Drug Metabolism
• Canine Pharmacokinetics

Background:

• Mirtazapine (MRT), a human antidepressant, is used in dogs for anorexia, with dosages extrapolated from human data.
• Potential applications of MRT in dogs include antidepressant and analgesic effects.
• Understanding MRT's metabolism via cytochrome P450 into 8-OH mirtazapine (8-OH) and dimetilmirtazapine (DMR) is crucial for veterinary use.

Purpose of the Study:

• To determine the pharmacokinetic profile of Mirtazapine (MRT) and its primary metabolites (8-OH mirtazapine and dimetilmirtazapine) in healthy Beagle dogs.
• To compare the pharmacokinetics of MRT in dogs with data from other species.
• To provide foundational data for optimizing Mirtazapine dosage and efficacy in canine patients.

Main Methods:

• Oral administration of Mirtazapine (20 mg/dog) to six healthy male Beagle dogs.
• Plasma concentrations of MRT and its metabolites (8-OH and DMR) were measured using high-performance liquid chromatography with fluorescence detection.
• Pharmacokinetic parameters including half-life and clearance were calculated.

Main Results:

• Pharmacokinetic profiles of Mirtazapine (MRT) and dimetilmirtazapine (DMR) were similar, detected between 0.25 and 10 hours post-administration.
• 8-OH mirtazapine (8-OH) achieved the highest plasma concentrations, detected from 0.50 to 10 hours.
• The mean half-life of MRT was 6.17 hours, with a clearance of 1193 mL/h/kg.

Conclusions:

• Mirtazapine exhibits a distinct pharmacokinetic profile in dogs compared to humans and other species.
• The metabolite 8-OH mirtazapine reaches higher concentrations than the parent drug or DMR in dogs.
• These findings highlight the need for species-specific pharmacokinetic data to guide Mirtazapine's therapeutic use in veterinary medicine.